Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
78.89
-0.38 (-0.48%)
At close: Jun 26, 2026, 4:00 PM EDT
80.45
+1.55 (1.97%)
After-hours: Jun 26, 2026, 7:47 PM EDT
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 711 employees as of September 30, 2025. The number of employees increased by 102 or 16.75% compared to the previous year.
Employees
711
Change (1Y)
102
Growth (1Y)
16.75%
Revenue / Employee
$874,837
Profits / Employee
-$423,221
Market Cap
11.11B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Cytokinetics | 673 |
| Krystal Biotech | 295 |
ARWR News
- 5 days ago - Arrowhead receives MAA in the EU for REDEMPLO - TheFly
- 5 days ago - Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Business Wire
- 9 days ago - Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars - Business Wire
- 17 days ago - Arrowhead Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Arrowhead Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 25 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events - Business Wire
- 4 weeks ago - Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE - TheFly
- 4 weeks ago - Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026 - Business Wire